Clinical trial · Observational
Radiation-induced Toxicity in Prostate Cancer/ Standard-Follow-Up Program Prostate
Radiation Induced Toxicity in Prostate Cancer
NCT03034187CI-TRIAL-00070583SFP-PROSTATErecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal is to gain insight in the development and course of the toxicity after a curative treatment of prostate cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- 1. Change in Acute toxicity
- timeFrame
- Toxicity:First visit/Wekely during RT, Acute Toxicity: 2-wekely and at the end of RT/ 2 months after RT/1, 2, 3, 4, 5 years after RT
- description
- Common Terminology Criteria for Adverse Events, version 4.0 * CTCAE 4.0 Constipation * CTCAE 4.0 Diarrhea * CTCAE 4.0 Fecal Incontinence * CTCAE 4.0 Flatulance * CTCAE 4.0 Proctitis * CTCAE 4.0 Rectal Hemorrhage * CTCAE 4.0 Rectal Mucositis * CTCAE 4.0 Rectal Ulcer * CTCAE 4.0 Bladder spasm * CTCAE 4.0 Cystitis Noninfective * CTCAE 4.0 Hematuria * CTCAE 4.0 Urinary Frequency * CTCAE 4.0 Urinary Incontinence * CTCAE 4.0 Urinary retention * CTCAE 4.0 Urinary tract Obstruction * CTCAE 4.0 Urinary tract pain * CTCAE 4.0 Urinary Urgency * CTCAE 4.0 Erectile dysfunction
Secondary outcomes (1)
- measure
- 2. Change in patient -rated Quality-of-Life
- timeFrame
- First visit/End of RT/ 2 months after RT/1, 2, 3, 4, 5 years after RT
- description
- Questionnarys QLQ-PR25, QLQ-C30, International Index of Erectile Function
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All curative treated patients with prostatecancer( with positive lymph nodes) * All patients who will be treated with RT( including post-operative, adjuvant treatments) * Are willing to fill in toxicity and QOL-questionnarys (QLQ-PR25 en de QLQ-C30) Exclusion Criteria: Patients who are not willing to fill in toxicity and QOL-questionnarys Patients who will not get RT Non-curative or palliative treated patients (with bone mestasis) Non-prostate cancer-patients
References
Publications (0)
Data not yet available
No reference posted for this study.